IDXX Idexx Laboratoriesdata gap · 92% coverage
Health Care · Health Care Equipment · close $560.36 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Idexx Laboratories (IDXX) has a ThetaGrade House Rating of 56/100 (grade C), ranking #15 of 150 in Health Care. Its strongest pillars are profitability (80) and cash flow (65); its weakest is valuation (29). Data gap: 2 factors without usable data, so 92% of the method weight is covered. TTM revenue growth is 12.8% and operating margin 32.0%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 92% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 49| Revenue growth YoY (TTM) (13.3%) | 12.8% | 60 |
| EPS growth YoY (TTM) (13.3%) | 18.5% | 54 |
| Revenue acceleration (6.7%) | -4.6% | 18 |
Profitability
weight 18.5% (→20.0%) · 80| Operating margin (10.7%) | 32.0% | 90 |
| 4Q gross-margin change (9.3%) | 0.9% | 69 |
Balance sheet
weight 18.5% (→20.0%) · 58| Net debt / EBITDA (10.7%) | 0.16× | 69 |
| Current ratio (5.3%) | 1.17 | 14 |
| Interest coverage (4.0%) | 37.54× | 88 |
Cash flow
weight 12.33% (→13.3%) · 65| FCF margin (6.7%) | 24.6% | 84 |
| FCF yield (6.7%) | 2.4% | 45 |
Valuation
weight 12.33% (→13.3%) · 29| P/E (inverted) (6.7%) | 39.38× | 32 |
| EV/Sales (inverted) (6.7%) | 9.75× | 25 |
Technicals (EOD)
| RSI(14) | 66.0 |
| EMA 9 / 21 | 533.00 / 527.40 · crossed up 2d ago |
| 200-day SMA | 579.67 |
| Volume vs 20d avg | 1.33× |
| 20-day return | 10.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like IDXX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is IDXX's House Rating?
- IDXX scores 56 out of 100 (grade C) as of 2026-10-16, ranking #15 of 150 Health Care stocks we cover.
- What do analysts say about IDXX?
- We do not have enough analyst-sentiment data to score this stock.
- When does IDXX report earnings next?
- IDXX's next earnings report is estimated for about 2026-11-02 (window 2026-10-28 to 2026-11-07), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is IDXX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology